LT2663577T - Antikūnas, surišantis il-17a ir il-17f - Google Patents

Antikūnas, surišantis il-17a ir il-17f

Info

Publication number: LT2663577T
Authority: LT; Lithuania
Prior art keywords: antibody binding; antibody; binding
Prior art date: 2011-01-14

Application number

LTEP12700433.1T

Other languages

English (en)

Inventor

Ralph Adams

Terence Seward Baker

Alastair David Griffiths Lawson

Original Assignee

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-14

Filing date

2012-01-11

Publication date

2017-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45496193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2663577(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-01-11 Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl

2017-07-25 Publication of LT2663577T publication Critical patent/LT2663577T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Neurology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)

LTEP12700433.1T 2011-01-14 2012-01-11 Antikūnas, surišantis il-17a ir il-17f LT2663577T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161432814P	2011-01-14	2011-01-14
PCT/GB2012/050050 WO2012095662A1 (en)	2011-01-14	2012-01-11	Antibody molecules which bind il-17a and il-17f

Publications (1)

Publication Number	Publication Date
LT2663577T true LT2663577T (lt)	2017-07-25

Family

ID=45496193

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP12700433.1T LT2663577T (lt)	2011-01-14	2012-01-11	Antikūnas, surišantis il-17a ir il-17f
LTPA2022501C LTC2663577I2 (lt)	2011-01-14	2022-01-19

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2022501C LTC2663577I2 (lt)	2011-01-14	2022-01-19

Country Status (39)

Country	Link
US (6)	US8580265B2 (lt)
EP (2)	EP2663577B1 (lt)
JP (2)	JP6028737B2 (lt)
KR (1)	KR101950306B1 (lt)
CN (1)	CN103384682B (lt)
AR (2)	AR084845A1 (lt)
AU (1)	AU2012206431B2 (lt)
BR (1)	BR112013017951B1 (lt)
CA (1)	CA2823812C (lt)
CL (1)	CL2013002044A1 (lt)
CO (1)	CO6781516A2 (lt)
CY (2)	CY1119055T1 (lt)
DK (1)	DK2663577T3 (lt)
EA (1)	EA037071B1 (lt)
ES (1)	ES2632583T3 (lt)
FI (1)	FIC20220002I1 (lt)
FR (1)	FR22C1000I2 (lt)
HR (1)	HRP20171034T1 (lt)
HU (1)	HUS2200001I1 (lt)
IL (1)	IL227347B (lt)
LT (2)	LT2663577T (lt)
LU (1)	LUC00246I2 (lt)
MA (1)	MA34907B1 (lt)
ME (1)	ME02734B (lt)
MX (1)	MX341489B (lt)
MY (1)	MY162790A (lt)
NL (1)	NL301159I2 (lt)
NO (1)	NO2021053I1 (lt)
PH (1)	PH12013501435B1 (lt)
PL (1)	PL2663577T3 (lt)
PT (1)	PT2663577T (lt)
RS (1)	RS56298B1 (lt)
SG (2)	SG191906A1 (lt)
SI (1)	SI2663577T1 (lt)
TN (1)	TN2013000292A1 (lt)
TW (1)	TWI511978B (lt)
UA (1)	UA110358C2 (lt)
WO (1)	WO2012095662A1 (lt)
ZA (1)	ZA201306080B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0620729D0 (en) *	2006-10-18	2006-11-29	Ucb Sa	Biological products
GB0807413D0 (en) *	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
SG185354A1 (en)	2010-05-20	2012-12-28	Ablynx Nv	Biological materials related to her3
CN103384682B (zh)	2011-01-14	2017-04-12	Ucb医药有限公司	结合il‑17a和il‑17f的抗体分子
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2013259276B2 (en)	2012-05-10	2018-03-22	Bioatla Llc	Multi-specific monoclonal antibodies
GB201310544D0 (en)	2013-06-13	2013-07-31	Ucb Pharma Sa	Obtaining an improved therapeutic ligand
KR102278487B1 (ko) *	2013-11-18	2021-07-19	샹하이 헨그루이 파마수티컬 컴퍼니 리미티드	Ｉｌ-17ａ 접합체 및 이의 용도
JP2017507939A (ja)	2014-02-21	2017-03-23	ジェネンテック，インコーポレイテッド	抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
EP3142645A4 (en) *	2014-05-15	2017-12-27	Rani Therapeutics, LLC	Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3250927B1 (en)	2015-01-28	2020-02-19	H. Hoffnabb-La Roche Ag	Gene expression markers and treatment of multiple sclerosis
JP6931648B2 (ja) *	2015-10-27	2021-09-08	ユーシービーバイオファルマエスアールエル	抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
RU2680011C2 (ru) *	2016-04-29	2019-02-14	Закрытое Акционерное Общество "Биокад"	Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
EA201990673A1 (ru)	2016-09-14	2019-08-30	Бэйцзин Ханми Фарм. Ко., Лтд.	Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
US10858427B2 (en) *	2017-03-10	2020-12-08	Suzhou Kanova Biopharmaceutical Co., Ltd.	Monoclonal antibody against both IL-17A and IL-17F and use of the same
GB201719447D0 (en) *	2017-11-23	2018-01-10	Ucb Biopharma Sprl	Pharmaceutical composition
KR20210009421A (ko)	2018-06-14	2021-01-26	바이오아트라, 엘엘씨	다중 특이적 항체 구조체
WO2020024931A1 (en) *	2018-07-31	2020-02-06	Shen Weiqun	Anti-il-17a antibodies and use thereof
CN110151999A (zh) *	2019-05-22	2019-08-23	中国人民解放军第四军医大学	用于抑制恶性黑色素瘤进展的靶向药物
WO2021003739A1 (zh) *	2019-07-11	2021-01-14	武汉友芝友生物制药有限公司	四价对称双特异性抗体
GB201919061D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
EP4393948A1 (en) *	2022-12-28	2024-07-03	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
TW202515910A (zh) *	2023-06-22	2025-04-16	美商派拉岡醫療公司	Il-17抗體組合物及使用方法
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025238133A1 (en)	2024-05-17	2025-11-20	UCB Biopharma SRL	Multispecific antibody with binding specificity for il-11 and il-17

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP1997891A1 (en)	1988-09-02	2008-12-03	Dyax Corporation	Generation and selection of recombinant varied binding proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
AU7766391A (en)	1990-04-23	1991-11-11	Corvas International N.V.	Thrombus-specific antibody derivatives
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de)	1991-04-10	2009-01-02	Scripps Research Inst	Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE408012T1 (de)	1991-12-02	2008-09-15	Medical Res Council	Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1993022854A1 (en)	1992-04-27	1993-11-11	The Commonwealth Of Australia	Radio communication modem for receiving and estimating a transmitted symbol
US6274711B1 (en)	1993-06-14	2001-08-14	Inserm, Institut National De La Sante Et De La Recherche Medicale	Purified mammalian CTLA-8 antigens and related reagents
WO1995015982A2 (en)	1993-12-08	1995-06-15	Genzyme Corporation	Process for generating specific antibodies
DK1231268T3 (da)	1994-01-31	2005-11-21	Univ Boston	Polyklonale antistofbiblioteker
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
EP1591529A3 (en)	1995-07-19	2005-11-09	Genetics Institute, LLC	Human CLTA-8 and uses of CTLA-8-related proteins
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
WO1999037779A1 (en)	1998-01-22	1999-07-29	Genentech, Inc.	Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
EP1053751A1 (en)	1999-05-17	2000-11-22	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Compositions and methods for treating cell proliferation disorders
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
CN1646161A (zh)	2002-02-21	2005-07-27	杜克大学	自身免疫疾病的药剂和治疗方法
EP1570267B1 (en)	2002-12-03	2011-10-12	UCB Pharma, S.A.	Assay for identifying antibody producing cells
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
CA2527020A1 (en)	2003-07-01	2005-01-13	Celltech R & D Limited	Modified antibody fab fragments
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
EP1641822B1 (en)	2003-07-08	2013-05-15	Genentech, Inc.	Il-17 a/f heterologous polypeptides and therapeutic uses thereof
DK1983000T3 (en)	2003-11-21	2015-12-07	Ucb Biopharma Sprl	A method for the treatment of multiple sclerosis by inhibiting IL-17 activity
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
GB0425569D0 (en)	2004-11-19	2004-12-22	Celltech R&D Ltd	Biological products
KR20070107687A (ko)	2004-12-31	2007-11-07	제넨테크, 인크.	Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
TW200641353A (en)	2005-02-14	2006-12-01	Wyeth Corp	Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
US7704503B2 (en)	2005-02-14	2010-04-27	Wyeth Llc	Use of IL-17F in diagnosis and therapy of airway inflammation
ES2353117T3 (es) *	2005-09-28	2011-02-25	Zymogenetics, Inc.	Antagonistas de il-17a e il-17f y métodos de uso de los mismos antagonistas de il-17a e il-17f y métodos de uso de los mismos.
DK1963368T6 (da)	2005-12-13	2020-06-29	Lilly Co Eli	Anti-il-17-antistoffer
EP2377887A1 (en) *	2006-03-10	2011-10-19	Zymogenetics Inc	Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7790163B2 (en)	2006-03-10	2010-09-07	Zymogenetics, Inc.	Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en)	2006-06-23	2008-04-01	Astrazeneca Ab	Compounds
GB0612928D0 (en)	2006-06-29	2006-08-09	Ucb Sa	Biological products
US7846443B2 (en)	2006-08-11	2010-12-07	Schering Corporation	Antibodies to IL-17A
GB0620729D0 (en) *	2006-10-18	2006-11-29	Ucb Sa	Biological products
CL2008000883A1 (es)	2007-03-28	2008-10-03	Wyeth6 3	Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
WO2008134659A2 (en)	2007-04-27	2008-11-06	Zymogenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
AU2007352412B2 (en) *	2007-04-27	2013-05-16	Zymogenetics, Inc.	Antibodies that bind both IL-17A and IL-17F and methods of using the same
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
GB0807413D0 (en) *	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
KR20170023209A (ko)	2008-05-05	2017-03-02	노비뮨 에스 에이	항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US8790642B2 (en)	2008-08-29	2014-07-29	Genentech, Inc.	Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010035012A1 (en)	2008-09-26	2010-04-01	Ucb Pharma S.A.	Biological products
KR101730675B1 (ko)	2009-07-14	2017-05-11	웨이브텍 비젼 시스템스, 인크.	안과 수술 측정 시스템
EP2475682B1 (en)	2009-09-10	2018-01-31	UCB Biopharma SPRL	Multivalent antibodies
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
CN103384682B (zh)	2011-01-14	2017-04-12	Ucb医药有限公司	结合il‑17a和il‑17f的抗体分子

2012
- 2012-01-11 CN CN201280009581.4A patent/CN103384682B/zh active Active
- 2012-01-11 ES ES12700433.1T patent/ES2632583T3/es active Active
- 2012-01-11 PH PH1/2013/501435A patent/PH12013501435B1/en unknown
- 2012-01-11 SG SG2013052741A patent/SG191906A1/en unknown
- 2012-01-11 WO PCT/GB2012/050050 patent/WO2012095662A1/en not_active Ceased
- 2012-01-11 HR HRP20171034TT patent/HRP20171034T1/hr unknown
- 2012-01-11 PL PL12700433T patent/PL2663577T3/pl unknown
- 2012-01-11 JP JP2013548889A patent/JP6028737B2/ja active Active
- 2012-01-11 DK DK12700433.1T patent/DK2663577T3/en active
- 2012-01-11 MX MX2013007956A patent/MX341489B/es active IP Right Grant
- 2012-01-11 US US13/348,456 patent/US8580265B2/en active Active
- 2012-01-11 RS RS20170705A patent/RS56298B1/sr unknown
- 2012-01-11 KR KR1020137021367A patent/KR101950306B1/ko active Active
- 2012-01-11 EA EA201300819A patent/EA037071B1/ru unknown
- 2012-01-11 EP EP12700433.1A patent/EP2663577B1/en active Active
- 2012-01-11 SG SG10201510762YA patent/SG10201510762YA/en unknown
- 2012-01-11 PT PT127004331T patent/PT2663577T/pt unknown
- 2012-01-11 BR BR112013017951-1A patent/BR112013017951B1/pt active IP Right Grant
- 2012-01-11 EP EP17163570.9A patent/EP3219728A1/en not_active Withdrawn
- 2012-01-11 SI SI201230994T patent/SI2663577T1/sl unknown
- 2012-01-11 CA CA2823812A patent/CA2823812C/en active Active
- 2012-01-11 MY MYPI2013701205A patent/MY162790A/en unknown
- 2012-01-11 LT LTEP12700433.1T patent/LT2663577T/lt unknown
- 2012-01-11 AU AU2012206431A patent/AU2012206431B2/en active Active
- 2012-01-11 ME MEP-2017-146A patent/ME02734B/me unknown
- 2012-01-11 MA MA36181A patent/MA34907B1/fr unknown
- 2012-01-12 AR ARP120100115A patent/AR084845A1/es active IP Right Grant
- 2012-01-12 TW TW101101182A patent/TWI511978B/zh active
- 2012-11-01 UA UAA201309003A patent/UA110358C2/ru unknown
2013
- 2013-07-04 IL IL227347A patent/IL227347B/en active IP Right Grant
- 2013-07-10 TN TNP2013000292A patent/TN2013000292A1/fr unknown
- 2013-07-12 CL CL2013002044A patent/CL2013002044A1/es unknown
- 2013-08-12 CO CO13191259A patent/CO6781516A2/es not_active Application Discontinuation
- 2013-08-13 ZA ZA2013/06080A patent/ZA201306080B/en unknown
- 2013-11-08 US US14/074,880 patent/US9034600B2/en active Active
2015
- 2015-04-20 US US14/690,892 patent/US9988446B2/en active Active
2016
- 2016-10-03 JP JP2016195952A patent/JP2017046699A/ja active Pending
2017
- 2017-07-12 CY CY20171100738T patent/CY1119055T1/el unknown
2018
- 2018-05-08 US US15/974,407 patent/US20180346561A1/en not_active Abandoned
2020
- 2020-12-15 US US17/122,752 patent/US11919950B2/en active Active
2021
- 2021-12-20 NO NO2021053C patent/NO2021053I1/no unknown
- 2021-12-22 LU LU00246C patent/LUC00246I2/en unknown
2022
- 2022-01-04 FR FR22C1000C patent/FR22C1000I2/fr active Active
- 2022-01-10 HU HUS2200001C patent/HUS2200001I1/hu unknown
- 2022-01-11 CY CY2022002C patent/CY2022002I2/el unknown
- 2022-01-12 FI FIC20220002C patent/FIC20220002I1/fi unknown
- 2022-01-19 LT LTPA2022501C patent/LTC2663577I2/lt unknown
- 2022-01-19 NL NL301159C patent/NL301159I2/nl unknown
- 2022-12-21 AR ARP220103527A patent/AR128047A2/es unknown
2024
- 2024-01-25 US US18/422,323 patent/US20240376191A1/en active Pending

Also Published As

Publication number	Publication date
US9988446B2 (en)	2018-06-05
AR128047A2 (es)	2024-03-20
IL227347B (en)	2018-06-28
LTPA2022501I1 (lt)	2022-02-10
TW201238975A (en)	2012-10-01
US8580265B2 (en)	2013-11-12
CY2022002I1 (el)	2022-03-24
US20240376191A1 (en)	2024-11-14
US20140065674A1 (en)	2014-03-06
MX341489B (es)	2016-08-23
LUC00246I2 (lt)	2025-02-03
US11919950B2 (en)	2024-03-05
BR112013017951B1 (pt)	2022-09-27
CA2823812C (en)	2017-02-14
ES2632583T3 (es)	2017-09-14
AR084845A1 (es)	2013-06-26
NZ613286A (en)	2014-11-28
ZA201306080B (en)	2014-10-29
AU2012206431B2 (en)	2015-04-30
FR22C1000I2 (fr)	2022-12-30
US20120183558A1 (en)	2012-07-19
UA110358C2 (en)	2015-12-25
DK2663577T3 (en)	2017-07-17
KR101950306B1 (ko)	2019-02-20
JP2017046699A (ja)	2017-03-09
RS56298B1 (sr)	2017-12-29
PL2663577T3 (pl)	2017-09-29
IL227347A0 (en)	2013-09-30
HUS2200001I1 (hu)	2022-02-28
US20210309734A1 (en)	2021-10-07
JP2014505474A (ja)	2014-03-06
CL2013002044A1 (es)	2014-05-09
KR20140005964A (ko)	2014-01-15
SI2663577T1 (sl)	2017-08-31
US20180346561A1 (en)	2018-12-06
CN103384682B (zh)	2017-04-12
EA037071B1 (ru)	2021-02-02
NL301159I1 (lt)	2022-01-26
PH12013501435A1 (en)	2013-09-09
CO6781516A2 (es)	2013-10-31
TWI511978B (zh)	2015-12-11
PH12013501435B1 (en)	2019-02-01
MY162790A (en)	2017-07-14
MX2013007956A (es)	2013-08-01
NL301159I2 (nl)	2022-02-10
HRP20171034T1 (hr)	2017-10-06
EA201300819A1 (ru)	2014-01-30
WO2012095662A1 (en)	2012-07-19
EP2663577A1 (en)	2013-11-20
EP2663577B1 (en)	2017-04-12
LTC2663577I2 (lt)	2024-12-10
PT2663577T (pt)	2017-07-19
MA34907B1 (fr)	2014-02-01
CY1119055T1 (el)	2018-01-10
FR22C1000I1 (fr)	2022-02-18
BR112013017951A2 (pt)	2017-10-10
ME02734B (me)	2017-10-20
US20150218271A1 (en)	2015-08-06
FIC20220002I1 (fi)	2022-01-12
AU2012206431A1 (en)	2013-05-02
TN2013000292A1 (en)	2015-01-20
CN103384682A (zh)	2013-11-06
EP3219728A1 (en)	2017-09-20
CA2823812A1 (en)	2012-07-19
CY2022002I2 (el)	2022-05-27
SG191906A1 (en)	2013-08-30
SG10201510762YA (en)	2016-01-28
NO2021053I1 (no)	2021-12-20
US9034600B2 (en)	2015-05-19
JP6028737B2 (ja)	2016-11-16

Publication	Publication Date	Title
HUS2200001I1 (hu)	2022-02-28	IL-17A-hoz és IL-17F-hez kötõdõ ellenanyag
HUS1900048I1 (hu)	2019-11-28	Anti-IL-23 antitestek
ZA201404481B (en)	2016-01-27	Il-1 binding proteins
LT2852615T (lt)	2019-02-11	Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
IL222980A0 (en)	2013-02-03	Il-1 binding proteins
SG11201401649VA (en)	2014-07-30	Albumin binding antibodies and binding fragments thereof
EP2566517A4 (en)	2015-05-20	BINDER ANTIBODY CSF1R
HRP20180952T1 (hr)	2018-07-27	Anti-dll3 antitijelo
IL226157A0 (en)	2013-06-27	Antigen binding proteins
GB201113890D0 (en)	2011-09-28	Binding surfaces
GB201016809D0 (en)	2010-11-17	Improvements in relation to antibody binding